2012
DOI: 10.1038/bmt.2012.169
|View full text |Cite
|
Sign up to set email alerts
|

Rescuing the neonatal brain from hypoxic injury with autologous cord blood

Abstract: Brain injury resulting from perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality in infants and chronic neurologic disability in surviving children. Recent multicenter clinical trials demonstrated the effectiveness of hypothermia initiated within the first 6 postnatal hours to reduce the risk of death or major neurological disabilities among neonates with HIE. However, in these trials, approximately 40% of cooled infants died or survived with significant impairments. Therefore, a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
46
1
2

Year Published

2013
2013
2018
2018

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 55 publications
(49 citation statements)
references
References 119 publications
(145 reference statements)
0
46
1
2
Order By: Relevance
“…Limited data exist for autologous cord blood therapy and autologous bone marrow mesenchymal cell therapy. 34,35 Some follow-up safety data are becoming available. 36 Despite this recent progress, designing cell therapy studies remains challenging, and ethical concerns need to be addressed.…”
Section: New Therapeutic Resources and Researchmentioning
confidence: 99%
“…Limited data exist for autologous cord blood therapy and autologous bone marrow mesenchymal cell therapy. 34,35 Some follow-up safety data are becoming available. 36 Despite this recent progress, designing cell therapy studies remains challenging, and ethical concerns need to be addressed.…”
Section: New Therapeutic Resources and Researchmentioning
confidence: 99%
“…Multiple therapeutic trials are currently being conducted to investigate effective antiapoptotic therapy against HII. [5][6][7][8] Therefore, the availability of a technique to image apoptotic cell death in vivo is of considerable interest.…”
Section: Introductionmentioning
confidence: 99%
“…Increasing use of preimplantation genetic diagnosis (PGD) with HLA matching in Thalassemia endemic regions as South East Asia will see the rise of subsequent related allogeneic cord blood stem cell transplantation both in Thalassemia [9] but also other hereditary conditions [8,9]. Increasing favourable evidence for the potential of autologous UCB in cerebral palsy [10][11][12][13], traumatic and/ or hypoxic brain injury [14,15], diabetes [6,7] and deafness [6,7] may influence UCB banking [16,17]. Hepatitis B virus (HBV) infection remains a major global public health problem, despite the availability of a highly effective vaccine and improvements in antiviral therapy [18].…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, in view of the recent evidence of UCB's HSC plasticity and the strong evidence supporting the concept that HSCs are pluripotent and the source for the majority, if not all, of the cell types in our body [5], autologous and related allogeneic UCB stem cell storage offers an opportunity for many families for use in future regenerative medical purposes [6,7]. Increasing use of preimplantation genetic diagnosis (PGD) with HLA matching and subsequent related allogeneic cord blood HSCT in Thalassemia [8,9], endemic in South East Asia, and other hereditary conditions [8] and along with favourable support for autologous UCB use in cerebral palsy [10,11,12,13], traumatic and/or hypoxic brain injury [14,15], diabetes [6,7], and deafness [6,7] has already started transforming the field of UCB banking.…”
Section: Introductionmentioning
confidence: 99%